Europe’s drug regulator says it has identified another rare blood condition as a potential side effect of AstraZeneca’s COVID-19 vaccine.
It said it was looking into cases of heart inflammation after inoculation with all coronavirus vaccines.
The European Medicines Agency’s (EMA) safety committee said that capillary leak syndrome must be added as a new side effect to labelling on AstraZeneca’s vaccine, known as Vaxzevria.
People who had the condition, where fluids leak from the smallest blood vessels causing swelling and a drop in blood pressure, should not receive the shot.
The committee reviewed six validated cases of capillary leak syndrome in people who received the the vaccine. They were mostly female and one person subsequently died.
Reports that Oxford-AstraZeneca vaccine causes blood clots
